Article Text

Download PDFPDF

AB0340 Clinical efficacy of statins in patients with rheumatoid arthritis
  1. L Mikulets,
  2. T Ilashchuk
  1. Department of Propedeutics of Internal Diseases, Higher State Educational Establishment of Ukraine “Bukovinian State Medical University”, Chernivtsi, Ukraine


Background Cardiovascular disease (CVD) is a major cause of mortality in patients with rheumatoid arthritis (RA). In the literature there are conflicting data on the use of statins in patients with RA, indicating a lack of attention to the issue of prevention of CVD in this category of patients.

Objectives The aim of the study was to improve the efficiency of the treatment of rheumatoid arthritis by including to the basic treatment rosuvastatin.

Methods The study included 43 patients with RA. A survey conducted by the protocol patients (DAS28 index, visual analog scale (VAS), morning stiffness). The study of lipid metabolism included: determining the level of total cholesterol (total cholesterol), HDL cholesterol (HDL) and low density (LDL), atherogenic index (AI), triglycerides (TG). Total cardiovascular risk assessment was performed using a table SCORE. Surveyed patients divided into groups: primary (n=20) (basic therapy and rosuvastatin, 10 mg 1 time per day) and comparison (n=23) (basic therapy that included methotrexate, non-steroidal anti-inflammatory drugs, glucocorticoids in medium therapeutic doses).

Results As a result of the treatment found that patients with a primary and group comparison, there was a positive dynamics of clinical indicators of inflammatory activity (DAS28, VAS, morning stiffness). In the study group experienced a significant decrease (p<0.05) at the same time as in the comparison group had a tendency to decrease. Noted a reduction parameters: CRP (Δ137% main group and the comparison group Δ221%), ESR (Δ139% and Δ226% respectively). Also noted the changes in the lipid profile. Significantly decreased in the study group performance total cholesterol (Δ131% versus Δ215%), LDL cholesterol (Δ119% against Δ28%) and AI (Δ129% and Δ216% respectively).

Conclusions Inclusion in the complex therapy of patients with RA statins contributes to a significant reduction in total cholesterol, LDL cholesterol, and positively affects the activity of the process, reducing the levels of acute phase proteins. Additional indications for the purpose of statins have high activity process and late onset. The use of statins in RA, given their lipid-lowering and anti-inflammatory effects, may be an effective means for the successful prevention of cardiovascular complications.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.